BlackThorn starts enrolment in Phase IIa trial for MDD drug

US-based biopharmaceutical firm BlackThorn Therapeutics has started patient enrolment in a Phase IIa clinical trial of BTRX-246040 to treat adults with major depressive disorder (MDD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news